Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 250 participants.
Also called NCT05180773
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 250 participants
- Registry
-
NCT05180773
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT05180773. Randomized; quadruple masking; primary purpose treatment. Start 2022-07-27 (actual); primary completion 2028-06-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
- Acronym
- REBIRTH
- Condition
- Peripartum Cardiomyopathy, Postpartum
- Intervention (Drug)
- Bromocriptine
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Guideline Directed Medical Therapy for Heart Failure (GDMT)
- Intervention (Drug)
- Rivaroxaban
- Intervention (Drug)
- Second Placebo
- Lead sponsor
- Dennis M. McNamara, MD, MS
- Collaborator
- National Heart, Lung, and Blood Institute (NHLBI)
Record details
- Record id
cardio:ct-nct05180773- Content hash
3cddeacc9c0e8a2607cc9284a71ce387dc8ad0d748e223ddb5d9cb9662cb3197